Sun Pharma Gets CDSCO Panel Nod To study Semaglutide solution for Injection

This came after Sun Pharma presented the BE study report along with revised clinical trial (CT) protocol no. ICR/23/013 ver. 3.0 dated 16th Jan 2025 before the committee.

Semaglutide is a glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults.

GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas. Semaglutide is 94% similar to human GLP-1. Analogs of this hormone, such as semaglutide, stimulate the synthesis of insulin by stimulating pancreatic islet cells and reducing glucagon secretion. They directly bind with selectivity to the GLP-1 receptor, causing various beneficial downstream effects that reduce blood glucose in a glucose-dependent fashion.

At the recent SEC meeting for Endocrinology and Metabolism held on 25th March 2025, the expert panel reviewed the BE study report along with revised CT protocol no. ICR/23/013 ver. 3.0 dated 16th Jan 2025.

After detailed deliberation, the committee recommended accepting the bioequivalence study report and recommended granting permission to conduct the Phase III clinical trial study as per the revised protocol presented.

Also Read: Cipla gets CDSCO Panel nod for Phase-III CT of Inhaled Itraconazole dry powder for inhalation 10 mg capsules